New pill for PKU shows promise in teen trial

NCT ID NCT06637514

First seen Apr 24, 2026 · Last updated May 15, 2026 · Updated 2 times

Summary

This study tested an experimental drug called JNT-517 in 14 teenagers with phenylketonuria (PKU), a genetic condition that causes harmful buildup of an amino acid. Participants took either the drug or a placebo twice daily for 28 days to check safety and how the body processes it. The goal is to see if JNT-517 can help control PKU without requiring a strict diet.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHENYLKETONURIA (PKU) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Medical Center Dallas

    Dallas, Texas, 75235, United States

  • Murdoch Children's Research Institute

    Parkville, Melbourne, Victoria, 3052, Australia

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • University of Florida (UF) Health Shands Hospital

    Gainesville, Florida, 32608, United States

  • University of South Florida

    Tampa, Florida, 33606, United States

  • University of Texas Health (UTHealth) Science Center at Houston

    Houston, Texas, 77030, United States

  • Utah Health - The University of Utah Hospital

    Salt Lake City, Utah, 84112, United States

Conditions

Explore the condition pages connected to this study.